A neurodegenerative disease, multiple sclerosis (MS) is estimated to affect more than 1.8 million people worldwide — across all ages, races, sexes, and geographical regions. During Multiple Sclerosis Awareness Month this March, patients, caregivers, and other advocates are coming together to provide opportunities to connect, educate, inspire, empower, and…
I’ve noticed a lot of people with multiple sclerosis (MS) report that their disease worsens in the summer months, with fatigue and heat intolerance as common complaints. Not me. I seem to thrive in warmer weather, and I enjoy going outside for the heat. Instead, I struggle in the…
A young Michael Lama Jr. poses with his sister, Desiree Lama, at Christmastime years ago. (Photos courtesy of Michael Lama Jr.) Day 3 of 31 This is Michael Lama Jr.’s story: Growing up, my sister Desiree and I used to play video games and sports in our grandma’s backyard.
Note: This study was updated March 3, 2025, to correct that a ketogenic diet is a low-carbohydrate, high-fat diet. Eating a version of the low-carbohydrate, high-fat ketogenic diet for six months led to an anti-inflammatory shift in immune cell populations among people with stable, relapsing-remitting multiple sclerosis (RRMS)…
From left, Michael Lee Martinez and Feliciano Velazquez celebrate the holiday with their cats, Korra and Cleo, on Dec. 23, 2024. (Photos courtesy of Michael Lee Martinez) Day 2 of 31 This is Michael Lee Martinez’s story: Picture this: After stanning one of the biggest pop stars of our…
Sanam Saeedi resolved not to allow a diagnosis of MS to determine the course her life could take. (Photos courtesy of Sanam Saeedi) Day 1 of 31 This is Sanam Saeedi’s story: For years, I lived with numbness and tingling in my toes, but dismissed it as a result…
Treatment with Ocrevus (ocrelizumab) may have a beneficial effect on paramagnetic rim lesions — known as PRL, these are a type of chronic inflammatory lesion — in people with multiple sclerosis (MS), according to a newly shared analysis. PRLs, a form of nerve damage seen in MS, have…
I was driving home the other day when something in my rearview mirror caught my attention: A giant pickup truck had flipped over in the fast lane of the highway. It did not look good. I pulled over on the left shoulder and ran to help, completely forgetting the back…
Immune cells from people with multiple sclerosis (MS) exhibit distinct gene activity just before patients have a disease relapse, according to recent research. The observed immune perturbations, which are no longer observed by the time the relapse is actively underway, are consistent with the body’s response to a reactivation…
A friend of mine went hiking alone during the warmer months of early autumn. Before he left, he contacted several of his friends via a group chat and let us know when and where he intended to start and the location where he planned to camp for the night. He…
A noninvasive brain stimulation technique called transcranial direct current stimulation (tDCS) doesn’t seem to ease fatigue in adults with multiple sclerosis (MS) when given at home with computer-based cognitive training, according to one of the largest studies of its kind. While the home-based intervention was deemed feasible, combining daily…
A statistical model that takes clinical and demographic factors into account could help guide treatment decisions in people with relapsing-remitting multiple sclerosis (RRMS) who haven’t yet started on a multiple sclerosis (MS) therapy, a study reports. “Our study offers a predictive tool that fulfills an unmet need for…
Over the past decade, diagnoses of multiple sclerosis (MS) in Finland have become faster and treatments now follow the latest evidence, with about five times as many patients receiving high-efficacy disease-modifying therapies (DMTs) as first-line options, a study finds. Drawing on registry data, researchers found that diagnoses are…
Tiziana Life Sciences is partnering with a contract development and manufacturing organization with expertise in intranasal drugs to accelerate the development and commercial launch of foralumab, a treatment designed to be sprayed into the nose. Tiziana’s medication is being investigated in an expanded access program (EAP) and a…
Antibodies against a protein found in neurons and in nerve supporting cells, may play a role in driving multiple sclerosis (MS), a study indicates. Researchers examined immune responses against more than 23,000 human proteins, and the MLC1 protein emerged as one of the top hit proteins targeted by immune…
Interactions between the body’s immune system and bacteria that live in the digestive tract — essentially, a person’s gut — become disrupted in multiple sclerosis (MS), a new study by U.S. researchers found. The human intestines are home to billions of bacteria and other microorganisms, collectively known as the…
Using an implantable scaffold to collect immune cells in mice, researchers have gained insights into the immunological mechanisms driving primary progressive multiple sclerosis (PPMS). Based on the findings, the scientists developed a treatment strategy to block specific inflammatory molecules, which eased MS severity in the mouse model. The study,…
Four more people with nonactive secondary progressive multiple sclerosis (SPMS) have received foralumab nasal spray — Tiziana Life Sciences’ therapy candidate for SPMS — via an expanded access program, the biotechnology company announced. That program allows patients who do not qualify for an ongoing Phase 2a clinical…
I don’t know if anyone else’s life works this way, but my life has a soundtrack. It varies depending on my mood and what’s going on at the moment, but at any given time there’s music in my background. These days it’s usually playing on one of the personal assistant…
Using Ocrevus (ocrelizumab) as a first-line treatment for early-stage relapsing forms of multiple sclerosis (MS) is significantly better at delaying disease progression than starting with a less effective drug and switching to Ocrevus later. That’s according to nine years of data from the OPERA I (NCT01247324) and…
Switching from anti-CD20 medications to less effective fumarate therapies is linked to reduced healthcare visits and costs related to infections after a year, without affecting the rate of relapses in stable multiple sclerosis (MS). That’s according to an analysis of a U.S. healthcare claims database, which compared switchers against…
Relapsing-remitting multiple sclerosis (RRMS) patients with low educational attainment are more likely to delay the start of disease-modifying therapies (DMTs) after a diagnosis than those with a high educational status, a Danish study suggests. Educational status wasn’t significantly associated with diagnostic delays after the onset of symptoms,…
My husband and I are both considering early retirement. We’d discussed it for the past five years but hadn’t made any firm decisions. Last month, we decided that we needed to get serious about planning for it. We met with a financial adviser for retirement planning advice at our investment…
In a new deal, TG Therapeutics will use MaxCyte’s engineering technology to develop and manufacture its off-the-shelf CAR T-cell therapy candidate azercabtagene zapreleucel — azer-cel for short — for adults with progressive forms of multiple sclerosis (MS). The experimental treatment is being advanced toward a Phase 1…
Navigating the uncertainty of living with relapsing-remitting multiple sclerosis (RRMS) brings a number of challenges, a study shows. That uncertainty is best described as the intangible, difficult to define space between hope — the sense that things might get better or at least not turn out so badly —…
Children with multiple sclerosis (MS) who were exposed to sunlight for at least half an hour per day during the first summer of life tend to have less disease relapses than those who received less sun exposure during that period, a study found. The risk of relapse was also…
Thanks in part to 2024 being a leap year, I’ve never published a column on Valentine’s Day. That won’t happen anytime soon, either, as the next time the holiday lands on a Thursday is 2030. While I’ve mentioned this holiday before, I’ve never written a column specifically about Valentine’s Day.
The Floodlight MS app, a digital health application used to track dexterity, walking function, and cognition in people with multiple sclerosis (MS), has been deemed cost-effective in a new analysis. Modeling simulations showed MS patients who use the app experience fewer relapses and slower disability progression, which would improve…
Note: This column describes the author’s own experiences with oxybutynin. Not everyone will have the same response to treatment. Consult your doctor before starting or stopping a therapy. A few years ago, I spent the summer at my mom’s apartment because I’d been living in college dorms and my semester…
Experts in Australia and New Zealand have published the first consensus guidelines for the care of adults with multiple sclerosis (MS) in those countries, a step designed to help general practitioners and neurologists navigate the new MS treatment landscape. “Through these guidelines, we aim to support safe, timely and…
Get regular updates to your inbox.
